BRPI0910058A2 - agentes adrenérgicos alfa 2 de subtipo seletivo e métodos para uso dos mesmos - Google Patents

agentes adrenérgicos alfa 2 de subtipo seletivo e métodos para uso dos mesmos

Info

Publication number
BRPI0910058A2
BRPI0910058A2 BRPI0910058-0A BRPI0910058A BRPI0910058A2 BR PI0910058 A2 BRPI0910058 A2 BR PI0910058A2 BR PI0910058 A BRPI0910058 A BR PI0910058A BR PI0910058 A2 BRPI0910058 A2 BR PI0910058A2
Authority
BR
Brazil
Prior art keywords
methods
adrenergic agents
selective subtype
subtype alpha
alpha
Prior art date
Application number
BRPI0910058-0A
Other languages
English (en)
Inventor
A. Takeuchi Janet
Li Ling
M. Heidelbaugh Todd
Chow Ken
M. Kedzie Karen
W. Gil Daniel
K. Fang Wenkui
Original Assignee
Allergan, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc filed Critical Allergan, Inc
Publication of BRPI0910058A2 publication Critical patent/BRPI0910058A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

agentes adrenérgicos alfa 2 de subtipo seletivo e métodos para uso dos mesmos. a invenção provê métodos para tratamento de dor em mamíferos. em particular, a invenção provê aminoimidazolinas, aminotiazolinas e aminooxazolinas bem definidas e composições farmacêuticas das mesmas para tratar dor.
BRPI0910058-0A 2008-03-24 2009-03-24 agentes adrenérgicos alfa 2 de subtipo seletivo e métodos para uso dos mesmos BRPI0910058A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3892808P 2008-03-24 2008-03-24
US61/038,928 2008-03-24
US12/408,823 US20090239918A1 (en) 2008-03-24 2009-03-23 Selective subtype alpha 2 adrenergic agents and methods for use thereof
US12/408,823 2009-03-23
PCT/US2009/038004 WO2009120648A1 (en) 2008-03-24 2009-03-24 Selective subtype alpha 2 adrenergic agents and methods for use thereof

Publications (1)

Publication Number Publication Date
BRPI0910058A2 true BRPI0910058A2 (pt) 2019-03-06

Family

ID=41089551

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910058-0A BRPI0910058A2 (pt) 2008-03-24 2009-03-24 agentes adrenérgicos alfa 2 de subtipo seletivo e métodos para uso dos mesmos

Country Status (10)

Country Link
US (1) US20090239918A1 (pt)
EP (1) EP2265269A1 (pt)
JP (1) JP2011515479A (pt)
KR (1) KR20100126821A (pt)
CN (1) CN102036664B (pt)
AU (1) AU2009228449A1 (pt)
BR (1) BRPI0910058A2 (pt)
CA (1) CA2719226A1 (pt)
RU (1) RU2010141940A (pt)
WO (1) WO2009120648A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212176A (en) * 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
WO2005063724A1 (en) * 2003-12-23 2005-07-14 Basf Aktiengesellschaft 1-(azolin-2-yl) amino-1,2-diphenylethane compounds for combatting insects, arachnids and nematodes
WO2008123821A1 (en) * 2007-03-01 2008-10-16 Albireo Ab 4, 5-dihydro-lh-imidazol-2-amine derivatives for use in the treatment of respiratory, cardiovascular, neurological or gastrointestinal disorders
WO2008115141A1 (en) * 2007-03-19 2008-09-25 Albireo Ab 4, 5-dihydro-1,3-thiazol-2-amine derivatives and their use in the treatment of respiratory, cardiovascular, neurological or gastrointestinal disorders

Also Published As

Publication number Publication date
JP2011515479A (ja) 2011-05-19
CN102036664A (zh) 2011-04-27
RU2010141940A (ru) 2012-04-27
KR20100126821A (ko) 2010-12-02
CN102036664B (zh) 2012-11-28
EP2265269A1 (en) 2010-12-29
US20090239918A1 (en) 2009-09-24
CA2719226A1 (en) 2009-10-01
AU2009228449A1 (en) 2009-10-01
WO2009120648A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
CY1120022T1 (el) Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
CY1117476T1 (el) Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
FR2964565B1 (fr) Composition cosmetique comprenant un polymere fixant et un agent antipelliculaire
BRPI0912292A2 (pt) composições e métodos para o uso de células no tratamento do tecido cardíaco.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0807132A2 (pt) enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas
MX2010007936A (es) Anticuerpo anti-nr-10 y su uso.
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CO6781549A2 (es) Uso de ligandos sigma en dolor por cáncer de huesos
NI200900071A (es) Compuestos de pirozolina y su uso y composiciones farmacéuticas. pc 33496a.
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
BR112017026303A2 (pt) composição de lenço com gel compreendendo fibra de gel superabsorvente
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2514 DE 12-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]